Income Statement (TTM)
Panacea Life Sciences Holdings, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 9 | 6 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 |
| Change (%) | -12.35 | -32.92 | -52.37 | -26.22 | -3.11 | -2.22 | 7.74 | -10.22 | -16.49 | 12.97 | -3.83 | -1.04 | 36.34 | 15.89 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 13 | 11 | 9 | 9 | 6 | 6 | 8 | 7 | 7 | 6 | 6 | 6 | 6 | 6 | 7 |
| Change (%) | -11.53 | -19.29 | -1.48 | -29.14 | 0.25 | 20.44 | -11.55 | -0.90 | -9.55 | 0.91 | -2.83 | -0.14 | 6.90 | 2.39 | |
| % of Revenue | 126.00 | 127.19 | 153.03 | 316.50 | 303.99 | 314.53 | 387.40 | 318.04 | 351.07 | 380.21 | 339.61 | 343.12 | 346.26 | 271.48 | 239.86 |
| Gross Operating Profit | -3 | -2 | -3 | -6 | -4 | -4 | -6 | -5 | -5 | -5 | -4 | -4 | -4 | -4 | -4 |
| Change (%) | -8.36 | 30.83 | 94.47 | -30.49 | 1.89 | 31.00 | -18.26 | 3.38 | -6.79 | -3.40 | -2.42 | 0.24 | -5.06 | -5.48 | |
| % of Revenue | -26.00 | -27.19 | -53.03 | -216.50 | -203.99 | -214.53 | -287.40 | -218.04 | -251.07 | -280.21 | -239.61 | -243.12 | -246.26 | -171.48 | -139.86 |
| SG&A | -2 | 3 | 3 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Change (%) | -225.67 | 8.54 | -55.39 | -13.86 | 29.75 | -53.56 | 121.57 | -1.86 | -28.70 | -18.58 | -6.68 | 1.83 | 72.16 | -0.58 | |
| % of Revenue | -21.70 | 31.12 | 50.35 | 47.16 | 55.06 | 73.74 | 35.02 | 72.01 | 78.72 | 67.20 | 48.43 | 47.00 | 48.36 | 61.07 | 52.39 |
| R&D | -0 | ||||||||||||||
| Change (%) | |||||||||||||||
| % of Revenue | -0.36 | ||||||||||||||
| OpEx | 11 | 14 | 12 | 10 | 8 | 8 | 9 | 8 | 8 | 7 | 7 | 7 | 7 | 8 | 8 |
| Change (%) | 33.49 | -13.82 | -14.83 | -27.16 | 4.77 | 6.39 | -0.51 | -1.08 | -13.06 | -2.02 | -3.31 | 0.10 | 14.89 | 1.85 | |
| % of Revenue | 103.94 | 158.31 | 203.38 | 363.66 | 359.05 | 388.26 | 422.42 | 390.06 | 429.79 | 447.41 | 388.04 | 390.12 | 394.62 | 332.55 | 292.25 |
| Operating Income | -0 | -5 | -6 | -8 | -6 | -6 | -6 | -6 | -6 | -6 | -5 | -5 | -5 | -6 | -5 |
| Change (%) | 1,196.48 | 18.94 | 21.48 | -27.51 | 7.81 | 9.37 | -3.07 | 2.08 | -12.02 | -6.33 | -3.13 | 0.49 | 7.62 | -4.19 | |
| % of Revenue | -3.94 | -58.31 | -103.38 | -263.66 | -259.05 | -288.26 | -322.42 | -290.06 | -329.79 | -347.41 | -288.04 | -290.12 | -294.62 | -232.55 | -192.25 |
| Interest Expense | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 |
| Change (%) | 21.52 | -3.41 | -6.15 | -18.84 | -0.62 | 16.17 | 22.24 | 26.96 | 2.78 | -5.91 | -10.54 | -11.68 | 2.18 | 3.18 | |
| % of Revenue | -12.09 | -16.76 | -24.14 | -47.56 | -52.31 | -53.66 | -63.75 | -72.33 | -102.29 | -125.89 | -104.84 | -97.53 | -87.05 | -65.24 | -58.08 |
| Net Income | -4 | -5 | -4 | -3 | -3 | -5 | -8 | -10 | -10 | -9 | -8 | -8 | -8 | -8 | -8 |
| Change (%) | 41.72 | -20.13 | -16.98 | -19.89 | 72.07 | 65.93 | 25.07 | -3.99 | -4.05 | -10.84 | -1.20 | -6.74 | 6.71 | -4.31 | |
| % of Revenue | -35.88 | -58.02 | -69.09 | -120.41 | -130.75 | -232.20 | -394.01 | -457.35 | -489.10 | -561.94 | -443.51 | -455.64 | -429.40 | -336.08 | -277.51 |
Source: Capital IQ
